UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 10, 2020

CARPARTS.COM, INC.

(Exact name of registrant as specified in its charter)

​

2050 W. 190^th Street, Suite 400, Torrance, CA 90504

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code (424) 702-1455

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

​

​

​

​

Appointment of New Director

​

On November 10, 2020, the Board of Directors (the “Board”) of CarParts.com, Inc. (the “Company”) appointed Dr. Lisa Costa as a Class III director of the Company, effective immediately, to serve until the 2021 Annual Meeting of Stockholders, or until her earlier death, disqualification, resignation or removal. The Board has determined that Dr. Costa is an independent director under the listing standards of the Nasdaq Global Market.

​

There are no family relationships between Dr. Costa and any director or executive officer of the Company and Dr. Costa does not have a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

​

In connection with Dr. Costa’s appointment to the Board, Dr. Costa will receive the standard compensation received by non-employee directors, which compensation was last described in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission (the “SEC”) on April 27, 2020 and is incorporated herein by reference. Dr. Costa will also enter the Company’s standard form of indemnification agreement, which was previously filed by the Company as Exhibit 10.7 to the Annual Report on Form 10-K filed with the SEC on March 11, 2016.

​

Departure of Director

On November 12, 2020, Joshua L. Berman notified the Company’s Board of his decision to resign, effective as of November 12, 2020, from the Board. Mr. Berman’s resignation was to pursue other opportunities and did not result from any disagreements with management or the Board. Mr. Berman was a Class II director of the Company and had served as Chairman of the Company’s Compensation Committee and as a member of the Board Nominating and Corporate Governance Committee.

​

​

Item 7.01.                                      Regulation FD Disclosure.

​

On November 12, 2020, the Company issued a press release announcing the appointment of Dr. Costa to the Board and issued a separate press release announcing the resignation of Mr. Berman from the Board. Copies of those press releases are attached as Exhibit 99.1 and Exhibit 99.2 to this Current Report and is incorporated herein by reference.

​

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report and Exhibit 99.1 hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall such information or that Exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

​

Item 9.01.Financial Statements and Exhibits.

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​